Talat Imran - 03 Feb 2022 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Role
Chief Executive Officer, Director
Signature
/s/ Josh Seidenfeld, Attorney-in-Fact for Talat Imran
Issuer symbol
RANI
Transactions as of
03 Feb 2022
Transactions value $
$0
Form type
4
Filing time
07 Feb 2022, 20:52:36 UTC
Previous filing
13 Sep 2021
Next filing
24 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RANI Class A Common Stock Other $0 -827,467 -100% $0* 0 03 Feb 2022 See footnote F1, F2
transaction RANI Class A Common Stock Other $0 +12,343 $0 12,343 03 Feb 2022 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Biologix Partners, LP and VH Rani, LP. distributed these shares to its limited partners on a pro rata basis, for no consideration.
F2 Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F3 VH Moll, L.P., is a limited partner of VH Rani, LP. VH Moll, L.P. therefore received 12,343 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person is a member of the general partner and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.